Brief: Bone Therapeutics Q3 Operating Loss Widens To 8.96 Million Euros

Biosenic SA

07/11/2018 06:14

Nov 7 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * Q3 OPERATING LOSS AMOUNTED TO EUR 8.96 MILLION COMPARED TO
EUR
8.76 MILLION FOR SAME PERIOD LAST YEAR
    * NET CASH AT END OF SEPTEMBER 2018 AMOUNTED TO EUR 8.41
MILLION
    * CASH USED IN OPERATING ACTIVITIES AMOUNTED TO € 10.47
MILLION
FOR THE FIRST NINE MONTHS OF 2018, COMPARED TO € 10.14 MILLION
FOR THE SAME PERIOD IN 2017.
    * PLANS TO REPORT TOP LINE RESULTS FROM 32 PATIENTS OF ALLOB
PHASE
IIA SPINAL FUSION STUDY IN MID-2019 AFTER A 12-MONTH FOLLOW-UP
    * CURRENTLY GENERATING THE NON-CLINICAL DATA REQUIRED FOR
THE
APPLICATION AND EXPECTS TO SUBMIT THE CTA FOR A MULTI-CENTRE,
RANDOMISED, CONTROLLED STUDY IN H2 2019.
    * CONFIRMS EXPECTED CASH BURN (EXCLUDING PROCEEDS FROM
FINANCING)
FOR FULL YEAR 2018 TO BE IN RANGE OF EUR 15-16 MILLION
    * COMPANY EXPECTS TO HAVE SUFFICIENT CASH TO CARRY OUT ITS
OBJECTIVES UNTIL END OF Q3 2019

Source text for Eikon:  ID:nGNE8DmXM1 
Further company coverage:  BOTHE.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))